Literature DB >> 19889634

Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance.

Kristin I Stanford1, Lianchun Wang, Jan Castagnola, Danyin Song, Joseph R Bishop, Jillian R Brown, Roger Lawrence, Xaiomei Bai, Hiroko Habuchi, Masakazu Tanaka, Wellington V Cardoso, Koji Kimata, Jeffrey D Esko.   

Abstract

Hepatic clearance of triglyceride-rich lipoproteins depends on heparan sulfate and low density lipoprotein receptors expressed on the basal membrane of hepatocytes. Binding and uptake of the lipoproteins by way of heparan sulfate depends on the degree of sulfation of the chains based on accumulation of plasma triglycerides and delayed clearance of triglyceride-rich lipoproteins in mice bearing a hepatocyte-specific alteration of N-acetylglucosamine (GlcNAc) N-deacetylase-N-sulfotransferase 1 (Ndst1) (MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., and Esko, J. D. (2007) J. Clin. Invest. 117, 153-164). Inactivation of Ndst1 led to decreased overall sulfation of heparan sulfate due to coupling of uronyl 2-O-sulfation and glucosaminyl 6-O-sulfation to initial N-deacetylation and N-sulfation of GlcNAc residues. To determine whether lipoprotein clearance depends on 2-O-and 6-O-sulfation, we evaluated plasma triglyceride levels in mice containing loxP-flanked conditional alleles of uronyl 2-O-sulfotransferase (Hs2st(f/f)) and glucosaminyl 6-O-sulfotransferase-1 (Hs6st1(f/f)) and the bacterial Cre recombinase expressed in hepatocytes from the rat albumin (Alb) promoter. We show that Hs2st(f/f)AlbCre(+) mice accumulated plasma triglycerides and exhibited delayed clearance of intestinally derived chylomicrons and injected human very low density lipoproteins to the same extent as observed in Ndst1(f/f)AlbCre(+) mice. In contrast, Hs6st1(f/f)AlbCre(+) mice did not exhibit any changes in plasma triglycerides. Chemically modified heparins lacking N-sulfate and 2-O-sulfate groups did not block very low density lipoprotein binding and uptake in isolated hepatocytes, whereas heparin lacking 6-O-sulfate groups was as active as unaltered heparin. Our findings show that plasma lipoprotein clearance depends on specific subclasses of sulfate groups and not on overall charge of the chains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889634      PMCID: PMC2804175          DOI: 10.1074/jbc.M109.063701

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Order out of chaos: assembly of ligand binding sites in heparan sulfate.

Authors:  Jeffrey D Esko; Scott B Selleck
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

3.  Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans.

Authors:  Roger Lawrence; Hong Lu; Robert D Rosenberg; Jeffrey D Esko; Lijuan Zhang
Journal:  Nat Methods       Date:  2008-04       Impact factor: 28.547

4.  The molecular phenotype of heparan sulfate in the Hs2st-/- mutant mouse.

Authors:  C L Merry; S L Bullock; D C Swan; A C Backen; M Lyon; R S Beddington; V A Wilson; J T Gallagher
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

5.  New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E.

Authors:  C P Libeu; S Lund-Katz; M C Phillips; S Wehrli; M J Hernáiz; I Capila; R J Linhardt; R L Raffaï; Y M Newhouse; F Zhou; K H Weisgraber
Journal:  J Biol Chem       Date:  2001-08-10       Impact factor: 5.157

6.  Identification of the proteoglycan binding site in apolipoprotein B48.

Authors:  Christofer Flood; Maria Gustafsson; Paul E Richardson; Stephen C Harvey; Jere P Segrest; Jan Borén
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

7.  Systemic inactivation of Hs6st1 in mice is associated with late postnatal mortality without major defects in organogenesis.

Authors:  Konstantin I Izvolsky; Jining Lu; Greg Martin; Kenneth H Albrecht; Wellington V Cardoso
Journal:  Genesis       Date:  2008-01       Impact factor: 2.487

8.  Redirecting the substrate specificity of heparan sulfate 2-O-sulfotransferase by structurally guided mutagenesis.

Authors:  Heather N Bethea; Ding Xu; Jian Liu; Lars C Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-20       Impact factor: 11.205

9.  Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides.

Authors:  Hélène G Bazin; Marcos A Marques; Albert P Owens; Robert J Linhardt; Keith A Crutcher
Journal:  Biochemistry       Date:  2002-06-25       Impact factor: 3.162

10.  Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.

Authors:  Anne P Beigneux; Remco Franssen; André Bensadoun; Peter Gin; Kristan Melford; Jorge Peter; Rosemary L Walzem; Michael M Weinstein; Brandon S J Davies; Jan A Kuivenhoven; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Stephen G Young
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-19       Impact factor: 8.311

View more
  47 in total

1.  Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability.

Authors:  Ding Xu; Mark M Fuster; Roger Lawrence; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

2.  2-O-Sulfated Domains in Syndecan-1 Heparan Sulfate Inhibit Neutrophil Cathelicidin and Promote Staphylococcus aureus Corneal Infection.

Authors:  Atsuko Hayashida; Shiro Amano; Richard L Gallo; Robert J Linhardt; Jian Liu; Pyong Woo Park
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

3.  Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.

Authors:  Keyang Chen; Ming-Lin Liu; Lana Schaffer; Mingzhen Li; Guenther Boden; Xiangdong Wu; Kevin Jon Williams
Journal:  Hepatology       Date:  2010-11-03       Impact factor: 17.425

4.  Role of heparan sulfate proteoglycans in optic disc and stalk morphogenesis.

Authors:  Zhigang Cai; Kay Grobe; Xin Zhang
Journal:  Dev Dyn       Date:  2014-05-06       Impact factor: 3.780

5.  Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans.

Authors:  Hans L Mooij; Sophie J Bernelot Moens; Philip L S M Gordts; Kristin I Stanford; Erin M Foley; Marjolein A W van den Boogert; Julia J Witjes; H Carlijne Hassing; Michael W Tanck; Michiel A J van de Sande; J Han Levels; John J P Kastelein; Erik S G Stroes; Geesje M Dallinga-Thie; Jeff D Esko; Max Nieuwdorp
Journal:  J Lipid Res       Date:  2015-01-07       Impact factor: 5.922

6.  Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.

Authors:  Miaomiao Li; Ding Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-07       Impact factor: 11.205

7.  Glucuronic acid epimerase is associated with plasma triglyceride and high-density lipoprotein cholesterol levels in Turks.

Authors:  Uğur Hodoğlugil; David W Williamson; Yi Yu; Lindsay A Farrer; Robert W Mahley
Journal:  Ann Hum Genet       Date:  2011-05       Impact factor: 1.670

8.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

9.  Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice.

Authors:  Brett E Crawford; Omai B Garner; Joseph R Bishop; David Y Zhang; Kevin T Bush; Sanjay K Nigam; Jeffrey D Esko
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

10.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.